Quốc gia: Vương quốc Anh
Ngôn ngữ: Tiếng Anh
Nguồn: VMD (Veterinary Medicines Directorate)
Ramipril
MSD Animal Health UK Limited
QC09AA05
Ramipril
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Cardio Vascular ACE inhibitor
Expired
1999-02-25
Revised: February 2021 AN: 01810/2021 Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vasotop 1.25 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each tablet contains ramipril 1.25mg Excipients: For full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Tablet. Beige oblong flavoured tablet with dark spots, half scored on both sides with embossing of “V” and “1.25” on both sides of score line. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of congestive heart failure (NYHA: decompensation grades II-IV). The product can be used in combination with diuretics, and the cardiac glycosides digoxin or methyl-digoxin. 4.3 CONTRAINDICATIONS Not to be used in haemodynamically relevant vascular stenosis (e.g. aortic stenosis) or obstructive hypertrophic cardiomyopathy. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The use of ACE inhibitors in dogs with hypovolaemia/dehydration (e.g. due to large doses of a diuretic, vomiting or diarrhoea) can lead to acute hypotension. In such cases the fluid and electrolyte status should first be balanced and treatment suspended until it is stabilised. This also applies if clinical signs of apathy or ataxia occur during treatment with the product (potential signs of hypotension). After these symptoms have subsided, the treatment should be continued at 50% of the original dose. Substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors, may contribute to Revised: February 2021 AN: 01810/2021 Page 2 of 8 lowering systemic blood pressure. This may result in pre-renal uraemia (azotaemia). Renal function should be monitored both before and seven days after commencement of treatment with ACE inhibitors. This also applies when the dosage of ACE inhibitor or of a concurrently administered diuretic is increased. It is advisable to periodically monitor renal function thro Đọc toàn bộ tài liệu